New State Pharmacy Lien Laws in 2026: What Changed

James Wong — Founder & Pharmacist, LienScripts | March 1, 2026 | 9 min read

Multiple states enacted new or amended healthcare provider lien statutes, 340B contract pharmacy access laws, PBM transparency requirements, and prior authorization reforms in 2025-2026. PI attorneys must understand how these legislative changes affect pharmacy lien strategy across jurisdictions.

State legislatures enacted significant changes to healthcare provider lien statutes, 340B contract pharmacy rules, PBM transparency requirements, and prior authorization timelines during the 2025-2026 legislative sessions. These changes directly affect how pharmacy liens attach, what amounts are recoverable, and which procedural requirements must be met in personal injury cases across multiple jurisdictions. PI attorneys practicing in affected states must update their pharmacy lien workflows to remain compliant and maximize recovery for clients.

• Thirteen states enacted 340B contract pharmacy access laws in 2025, affecting pharmacy reimbursement structures and drug pricing transparency
• Several states amended healthcare provider lien statutes to clarify pharmacy lien priority and attachment procedures
• PBM transparency laws in over 30 states now require disclosure of spread pricing and rebate retention, though pharmacy liens through LienScripts bypass PBM adjudication entirely
• Prior authorization reform in multiple states mandates 48-hour standard and 24-hour urgent response times
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation that meets documentation requirements across all jurisdictions

340B Program Changes Reshape Pharmacy Economics

The 340B Drug Pricing Program, which requires manufacturers to sell outpatient drugs at discounted prices to eligible healthcare organizations, underwent significant state-level changes in 2025. According to the Health Resources and Services Administration (HRSA), 340B-covered entities now include over 50,000 contract pharmacy arrangements nationwide.

Thirteen states enacted 340B contract pharmacy access laws in 2025 that restrict or regulate how covered entities use contract pharmacies. These laws affect the broader pharmacy economics landscape, but they do not directly change how pharmacy liens work in personal injury cases. However, attorneys should understand two indirect effects:

Pharmacy access changes. Some 340B-related pharmacy closures in underserved areas have reduced local pharmacy access. The LienScripts platform operates a national pharmacy network that maintains medication access regardless of local pharmacy closures.

Pricing transparency pressure. 340B reform is increasing pressure on drug pricing transparency across the pharmaceutical supply chain, which may eventually influence how courts evaluate reasonable pharmacy charges in lien disputes.

According to James Wong, PharmD, founder of LienScripts, "340B reform primarily affects the hospital and clinic side of pharmacy economics. For personal injury pharmacy liens, the critical factor remains the clinical documentation and the lien's legal attachment to the settlement. The LienScripts MERIT report provides that documentation in every jurisdiction."

[!KEY] 340B program changes affect pharmacy economics broadly but do not change how PI pharmacy liens attach or recover. The LienScripts national pharmacy network maintains access regardless of local 340B-related disruptions.

Healthcare Provider Lien Statute Amendments

Several states amended their healthcare provider lien statutes during the 2025-2026 sessions, with changes affecting pharmacy lien practice in the following areas:

Lien Priority and Attachment

States including Georgia, Tennessee, and North Carolina clarified the priority of healthcare provider liens relative to other creditor claims against settlement proceeds. Georgia's SB 68, effective January 2026, modified the collateral source rule and phantom damages doctrine, affecting how the full value of medical services (including pharmacy costs) is presented at trial.

Tennessee amended its healthcare provider lien statute to require more specific notice requirements, including itemized statements of charges within 30 days of the lien filing. Attorneys practicing in Tennessee should ensure their pharmacy lien partners comply with these updated notice provisions.

Lien Amount Limitations

Several tort reform measures enacted in 2025-2026 include provisions that cap or limit healthcare provider lien amounts. These caps vary by state and may apply differently to pharmacy liens versus medical provider liens. Attorneys should review state-specific caps before estimating net client recovery.

Filing and Notice Requirements

Updated filing requirements in multiple states now mandate electronic filing of healthcare provider liens, standardized lien notice formats, and specific timelines for lien notification to all parties. The LienScripts platform maintains compliance with filing requirements across all 50 states, automatically generating documentation that meets each jurisdiction's procedural standards.

[!KEY] Healthcare provider lien statutes are evolving across multiple states. PI attorneys should verify current filing, notice, and priority requirements in each jurisdiction where they handle cases.

Tort Reform Impacts on Pharmacy Liens

The 2025-2026 tort reform wave included several measures that affect pharmacy lien recovery in personal injury cases.

Damage caps. States that enacted or modified non-economic damage caps indirectly affect pharmacy lien recovery by limiting total settlement amounts from which liens are paid. When total recovery is capped, all lien holders compete for a smaller pool of proceeds.

Collateral source modifications. Florida's HB 837, which took full effect in cases filed after March 2024, continues to reshape how medical costs are presented in personal injury cases. The statute limits evidence of medical costs to amounts actually paid or owed, rather than full billed amounts. Several other states are considering similar legislation.

Lien reduction provisions. Some states have enacted or proposed statutory lien reduction formulas that automatically reduce healthcare provider liens when the settlement does not fully cover all claimed damages. Attorneys should understand whether statutory reduction applies to pharmacy liens in their jurisdiction.

For comprehensive state-by-state pharmacy lien requirements, see the LienScripts pharmacy lien laws by state guide.

[!KEY] Tort reform measures in multiple states affect pharmacy lien recovery through damage caps, collateral source modifications, and statutory lien reduction formulas. Attorneys must factor these provisions into settlement calculations.

PBM Transparency Laws

Over 30 states have enacted PBM transparency laws as of early 2026, according to the National Conference of State Legislatures (NCSL). These laws require pharmacy benefit managers to disclose spread pricing practices, rebate retention amounts, and formulary placement criteria. Key state developments include:

Spread pricing bans. Several states now prohibit PBMs from retaining the difference between what they charge health plans and what they reimburse pharmacies for Medicaid prescriptions. This is expanding to commercial plans in some jurisdictions.

Rebate pass-through requirements. States including Arkansas, West Virginia, and Oklahoma now require PBMs to pass through a specified percentage of manufacturer rebates to health plans or directly to patients.

Formulary transparency mandates. Multiple states require PBMs to publish formulary criteria and explain the clinical basis for formulary placement decisions.

While PBM transparency laws improve the insurance-based medication landscape, pharmacy liens through LienScripts bypass the PBM system entirely. Medications are dispensed based on clinical need without PBM adjudication, formulary restrictions, or step therapy requirements. Attorneys should understand PBM reforms to advise clients about their insurance options, but the lien pathway remains PBM-independent.

Prior Authorization Reform Takes Effect

Prior authorization reform legislation enacted across multiple states in 2025-2026 requires health insurers to respond to medication approval requests within shorter timeframes. According to the American Medical Association, 37 states have enacted some form of prior authorization reform as of January 2026.

Key provisions include:

• Standard PA response within 48 hours (down from 5-15 business days in many states)
• Urgent PA response within 24 hours
• Elimination of PA for medications stable for 90+ days
• Electronic PA submission mandates
• Gold-carding for providers with high approval rates

Despite these reforms, prior authorization still creates treatment delays for personal injury patients. Even a 48-hour turnaround represents a gap for patients in acute pain. The LienScripts pharmacy lien eliminates prior authorization entirely because medications are dispensed without insurance involvement.

[!KEY] Prior authorization reform reduces but does not eliminate medication access delays. Pharmacy liens through LienScripts bypass PA completely, ensuring same-day medication access for PI plaintiffs.

How These Changes Affect PI Attorney Strategy

The legislative landscape in 2026 requires PI attorneys to take several proactive steps:

Review state-specific lien filing requirements. Updated notice, filing, and itemization requirements vary by state. Ensure your pharmacy lien partner complies with current requirements in every jurisdiction where you handle cases.

Factor tort reform into settlement calculations. Damage caps, collateral source modifications, and statutory lien reduction formulas affect net client recovery. Calculate pharmacy lien amounts against updated state-specific recovery limitations.

Connect clients with pharmacy liens early. PBM transparency and PA reform improve insurance-based access incrementally, but pharmacy liens provide immediate, barrier-free medication access. Early enrollment through LienScripts eliminates treatment gaps that could weaken the case narrative.

Use MERIT documentation across jurisdictions. The LienScripts MERIT (Medication Evaluation & Rationale for Injury Treatment) report meets documentation standards across all states, providing consistent pharmacist-signed evidence regardless of jurisdiction-specific requirements.

Monitor ongoing legislation. Healthcare provider lien statutes continue evolving. Attorneys should subscribe to legislative tracking services and maintain awareness of pending bills that could affect pharmacy lien practice in their jurisdictions.